AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03402503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast buccal film
Description: Film with active investigational product (montelukast) inserted and applied on inner cheek
Study NCT03402503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo buccal film
Description: Film with placebo (no active drug) inserted and applied on inner cheek
Study NCT04985474 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Study NCT01378039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: comparison of treatment effect on different markers
Description: inhaled budesonide (400 µg BD) or placebo BD
Study NCT01590485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
Study NCT01590485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saffron
Description: 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
Study NCT04529863 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab claim is used as the reference group.
Study NCT04529863 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Description: Abatacept claim is used as the exposure group.
Study NCT02683746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized albiglutide DCC pen injector
Description: A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
Study NCT02683746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized albiglutide DCC pen injector matching placebo
Description: A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
Study NCT02683746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide liquid auto-injector
Description: A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Study NCT02683746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide liquid auto-injector matching placebo
Description: A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Study NCT01213576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg and ivermectin 200mcg/kg
Description: 400 mg orally given annually
Study NCT01213576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole and ivermectin
Description: albendazole 800 mg and ivermectin 400mg orally given annually
Study NCT01213576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg and ivermectin 200mcg/kg
Description: Albendazole 400mg and ivermectin 200mcg/kg given twice a year
Study NCT01213576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole 800mg and ivermectin 400mcg/kg bi-annually
Description: albendazole 800mg and ivermectin 400mcg/kg given twice a year
Study NCT01811264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Participation Aid
Description: The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
Study NCT02162407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
Study NCT02162407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human soluble insulin
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
Study NCT04787523 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Patients have received neoadjuvant radiotherapy
Study NCT04366999 — intervention group
Intervention type: PROCEDURE
Intervention: OAGB
Description: OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
Study NCT01591070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.1% tacrolimus once-weekly application for 10 weeks
Study NCT01591070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.1% tacrolimus twice weekly application for 10 weeks
Study NCT01097629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant High Dose (HD)
Description: Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study NCT01327222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal bevacizumab
Study NCT04254718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling
Description: Creation of a digital story about the infant with video and music selected by parents
Study NCT02424097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste
Description: MI Paste \& MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray
Study NCT02424097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,100pm F-toothpaste and 0.5%NaF rinse
Description: Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)
Study NCT01097629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant Low Dose (LD)
Description: Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study NCT01097629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study NCT02088463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mobilization (manual therapy)
Description: mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
Study NCT02088463 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mobilization
Description: placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
Study NCT02088463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound and infrared devices
Description: ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
Study NCT02088463 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound and infrared devices
Description: ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
Study NCT00694057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 10 mg per day (5 mg BID)
Study NCT00694057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules BID
Study NCT02663895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
Study NCT02911688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gamma tocopherol
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
Study NCT02911688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
Study NCT03820245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bixin
Description: Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
Study NCT03820245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Norbixin
Description: Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
Study NCT03820245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene
Description: Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
Study NCT03820245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
Study NCT02208245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound: Axillary block
Description: Ultrasound guided axillary block
Study NCT02208245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound: Infraclavicular block
Description: Ultrasound guided infraclvicular block
Study NCT02208245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
Study NCT02274688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Management
Description: Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
Study NCT00856310 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)
Study NCT01524991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)
Study NCT01524991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 Day 1 (all cycles)
Study NCT01524991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 10 mg/kg Day 1 (start cycle 3)
Study NCT01956214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Exercise
Description: receive FES while exercising
Study NCT01956214 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mock FES Exercise
Description: participants will receive Mock FES
Study NCT01498133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin-to skin contact
Description: Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
Study NCT03037281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Septic
Description: 30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
Study NCT04548557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin therapy
Description: It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
Study NCT02310009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (AN)
Study NCT02310009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Study NCT02310009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (CON)
Study NCT00790309 — intervention group
Intervention type: PROCEDURE
Intervention: Weight loss surgery
Description: Weight loss surgery
Study NCT00790309 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic abdominal surgeries
Description: laparoscopic abdominal surgeries
Study NCT01439698 — intervention group
Intervention type: DEVICE
Intervention: Radio Frequency ablation Probe
Description: Any probe that can conduct radiofrequency ablation within biliary ducts.
Study NCT04401020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442257
Description: Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
Study NCT03270956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)
Study NCT02088463 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound and infrared devices
Description: ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
Study NCT02337218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSUS Pain Management System
Description: An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
Study NCT02337218 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SENSUS Pain Management System
Description: An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
Study NCT03671447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU Usual Care
Description: The control condition delivered at ICU is usual care.
Study NCT03671447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-ICU
Description: The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
Study NCT00942318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir insulin, Aspart insulin, Metformin
Description: Insulin doses adapted by patients according to self monitoring blood glucose results.
Study NCT00942318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir insulin, Aspart insulin, Metformin
Description: Insulin doses adapted by patients according to self monitoring blood glucose results.
Study NCT02960568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: 30 mg oral primaquine one time
Study NCT02042820 — intervention group
Intervention type: OTHER
Intervention: In vivo confocal microscopy (IVCM)
Description: IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
Study NCT01606657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: The patient will receive irrigation as a part of their wound care
Study NCT01606657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Irrigation
Description: The patient will not receive irrigation as part of their wound care
Study NCT04012489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking
Description: Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
Study NCT04012489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air Stacking
Description: The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
Study NCT03138993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient decision aid
Description: Web-based patient decision aid plus a paper workbook.
Study NCT03138993 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General sleep education
Description: Web-based information about sleep plus a paper workbook
Study NCT01382147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
Description: Chemotherapy
Study NCT01382147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
Description: Chemotherapy
Study NCT03865797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
Study NCT03865797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control active
Description: Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
Study NCT04233918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: Part A: Single IV dose Part B \& C: IV dose Q4W
Study NCT01937104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60
Study NCT03575403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.